Leadership
Visionary at the helm.
Kimberly Layne Tomczyk is the Founder/Head Researcher at IMPRNT Corporation, a patent-pending cancer treatment platform. A published researcher and 12-year veteran of enterprise medical device health system sales — she brings a rare combination of clinical-commercial fluency, AI-native product development, and the conviction to take on one of medicine’s most challenging frontiers. Her published work includes “The Prenotion Law: A Cross-Disciplinary Framework for Waveform-Mediated Governance of Organic Persistence” (Zenodo, 2026). McKinsey BLP Graduate, 2024.
IMPRNT is advised by a bench of senior leaders spanning multiple fields of disciplines required to bring a Class II/III medical device from validation through global commercialization. All advisors are actively engaged and operating under NDA.
Strategic Leadership
Strategic Advisor — Sales Commercialization
30+ years in global medical device commercialization. Senior sales leadership and operational strategy spanning ophthalmology, specialty care, and surgical devices. Over a decade of executive leadership at a Fortune 500 medical device company driving global market expansion
Strategic Advisor — Global Marketing
30+ years in global marketing strategy, international brand architecture, and go-to-market execution across the medical device and healthcare sectors. Corporate communications leadership spanning Fortune 500 organizations. Direct senior relationships with top-tier Silicon Valley venture capital principals
Scientific & Clinical Advisory
Chief Development Officer
PhD oncology drug development leader. 20+ years spanning two global pharmaceutical companies. Co-Founded a clinical-stage oncology therapeutics company that raised $139M from tier-1 investors. Designed a groundbreaking trial program that opened 192 clinical sites with a median startup time of 3.6 weeks. FDA Fast Track designation secured
Clinical Operations & Regulatory Affairs
20 years directing Phase I–IV clinical trials across major academic medical centers. IND/IDE management and regulatory submissions. Dual-certified: CCRP (2005) and CPHQ (2021). ICH-GCP compliant. Deep expertise in immuno-oncology, bone marrow transplant, and cellular therapies
Regulatory & Legal
Senior Regulatory Consultant
Former global quality leadership at two Fortune 500 medical device companies across diabetes technology and diagnostic imaging divisions. FDA enforcement expertise spanning inspections, warning letters, consent decrees, and court injunctions. Published author, university lecturer, and incoming board member of an organization providing free regulatory education to 160+ universities globally
Regulatory Attorney & Firm Principal
Legal, engineering, and entrepreneurial expertise. Boutique firm specializing in high-tech medical device regulatory strategy, M&A due diligence, and FDA compliance
Finance, Procurement & Commercial Growth
CFO Consultant — Treasury & Capital Strategy
Certified Treasury Professional with demonstrated expertise scaling companies from $5M to $50M. Financial modeling, investor relations, and capital structure optimization. Treasury management, capital allocation, and strategic fundraising support
Procurement & Financial Operations
MBA with 25+ years in financial services and enterprise technology. Former Fortune 100 global banking leadership spanning product management, treasury operations, and digital transformation. Expanded platform client base to 300+ banks and credit unions. AI-first product strategy and 0→1 product builds
VP Growth / Chief Commercial Officer
$15M+ in revenue generated with a 65% enterprise close rate. 8,700+ professional followers. Healthcare C-suite relationships spanning Fortune 500 clients. Head of U.S. Growth at a top-10 global communications firm. Commercial strategy, enterprise sales, and brand positioning
Technical Operations Advisory Board
IMPRNT is currently vetting world-class CTO candidates across robotics, AI engineering, and intelligent systems. Advisors under active evaluation include a Harvard PhD in robotics and autonomous systems, a former Fortune 100 robotics and software engineering leader, and internationally recognized experts in AI-guided medical device architectures. Our CTO selection will reflect the caliber this device demands.
Every advisor on this board was identified, researched, and personally recruited by our founder through a rigorous process combining AI-powered global talent intelligence with direct professional outreach. Over 200+ candidates were evaluated. These are the leaders who answered the call.
A Once-In-A-Generation Opportunity
Eradicate Cancer
With Us.
This is a rare opportunity to be part of a life-saving solution that could fundamentally change the future of cancer treatment worldwide.
We welcome inquiries from investors, strategic partners, and clinical collaborators.
All technical discussions require executed NDA.